From Law360:

Conservative think tank the R Street Institute, which argued that many of the benefits of a de novo appeal are still available to patent applicants via administrative procedures at the USPTO. And contrary to concerns about harming small inventors, the group said such appeals are mostly exploited by “well-financed” pharmaceutical companies to add extra time on the back end of a patent term.